The latest developments across the GLP-1 landscape, from new drug approvals and clinical research to pricing changes and policy shifts. Stay informed on the updates that affect Ozempic, Wegovy, Mounjaro, and the wider category.
News & Updates
NIH researchers have uncovered new details about how GLP-1 receptor agonists work inside neurons to drive weight loss, opening a potential path toward more effective future therapies. The findings, published in May 2025, shed light on brain-level mechanisms that were previously poorly understood. Here is what the research means for people currently taking or considering GLP-1 medications.
The European Medicines Agency has recommended approving an oral form of semaglutide (Wegovy) for weight management. This is a significant step toward a pill-based GLP-1 option that could change how patients access and experience weight loss treatment.
Insurance co-pays for GLP-1 weight loss medications like Wegovy and Zepbound are climbing, and some plans are dropping coverage entirely. This guide breaks down what's changing, why it's happening, and what practical steps you can take to keep your costs manageable.
Australia has revealed a striking number of Ozempic users, reflecting a global pattern of surging GLP-1 medication demand. This article breaks down what that growth means for patients considering semaglutide, how supply and costs are affected, and what questions to ask your provider before starting.
The European Medicines Agency has recommended approval of an oral semaglutide pill under the Wegovy brand, marking the first time a GLP-1 weight-loss drug could be taken as a tablet in Europe. This is a significant shift for patients who avoid injections. Here is what we know so far and what it could mean for your treatment options.
Generic semaglutide, the active ingredient in Ozempic, is set to arrive at Canadian pharmacies this week at a significantly lower price than the brand-name version. This is a major development for patients managing type 2 diabetes and weight loss. Here is what Canadian patients and US readers watching this space should know.
Maryland's Drug Affordability Board has placed payment limits on Ozempic (semaglutide), marking one of the first state-level price caps on a major GLP-1 medication. This article breaks down what the decision means for patients, how it could affect your costs, and what to do if you live outside Maryland.
Medicare is implementing a $50 per month out-of-pocket cap on GLP-1 medications for eligible beneficiaries, offering significant savings for patients who use drugs like semaglutide or tirzepatide. This guide breaks down who qualifies, how the bridge program works, and what steps you should take right now.
